Figure 1 (Figure 1)
Chemical structure diagram of sodium zirconium cyclosilicate showing zirconium (Zr), silicon (Si), and oxygen (O) atoms as labeled.*
Lokelma Powder, For Suspension
Product Images NDC 50090-6501
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lokelma (NDC 50090-6501). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure_2 (Figure 2)
A forest plot showing the effect of co-administration with Lokelma (10 g and 15 g) on the pharmacokinetics (AUC and Cmax) of various drugs including amlodipine, atorvastatin, clopidogrel, dabigatran, furosemide, glipizide, levothyroxine, losartan, warfarin, tacrolimus, and cyclosporin. The X-axis represents the ratio of Lokelma plus co-administered drug to the co-administered drug alone, with confidence intervals depicted for each drug.*
Figure_3 (Figure 3)
A line graph depicting mean serum potassium levels (mEq/L) with 95% confidence intervals over time during acute and randomized withdrawal phases. The graph compares groups receiving LOKELMA 10 g t.i.d., placebo, and varying doses of 5 g q.d., 10 g q.d., and 15 g q.d., showing serum potassium trends across hours and days.*
Figure 4 (Figure 4)
A line chart showing mean serum potassium levels (mEq/L) over time in weeks with 95% confidence intervals. Data points include acute phase baseline (APBL), extension phase baseline (EPBL), titrated dose, and off treatment. The X-axis represents time in weeks, and the Y-axis represents mean serum potassium concentration. The chart includes sample sizes for each time point and annotations for acute phase baseline, extension phase baseline, last visit within 1 day of last dose (Exit), and end of study (EOS).*
Figure_5 (Image 01)
A line chart comparing serum potassium levels over time between Lokelma and placebo groups. The y-axis shows serum potassium values (mEq/L) with 95% confidence intervals, and the x-axis represents study days across screening, dose adjustment, evaluation, and follow-up phases. Lokelma shows a trend of decreasing serum potassium, while placebo remains relatively stable.*
Label Image (Lbl500906501)
LOKELMA 10 g oral suspension powder packet label from A-S Medication Solutions. The label states the active ingredient as sodium zirconium cyclosilicate and notes each packet contains 10 g of sodium zirconium cyclosilicate powder. The package includes 30 packets, with storage instructions to store at 59 to 86 degrees Fahrenheit.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
